Edwards Lifesciences Corp

Research Edwards Lifesciences Corp (EW) on Bullrun: valuation model: 25.6% overvalued, market cap USD 52.50B, P/E 49.5. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerEW
• ExchangeNYSE
• CountryUnited States
• SectorHealthcare
• IndustryMedical Devices
• CurrencyUSD
• Valuation signal25.6% overvalued
• Market capUSD 52.50B
• P/E49.5
• Financial periodFY2025
• RevenueUSD 6.07B
• Revenue growth11.5%
• Net incomeUSD 1.07B
• Free cash flowUSD 1.34B
• Gross margin78.0%

Valuation Snapshot

Bullrun's latest valuation model marks Edwards Lifesciences Corp as 25.6% overvalued; latest market cap is USD 52.50B; P/E is 49.5.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands.

Frequently asked questions

Is Edwards Lifesciences Corp overvalued or undervalued?

Bullrun's valuation model currently marks Edwards Lifesciences Corp as 25.6% overvalued.

What is Edwards Lifesciences Corp's market cap?

Edwards Lifesciences Corp's market capitalization is USD 52.50B.

What is Edwards Lifesciences Corp's P/E ratio?

Edwards Lifesciences Corp's price-to-earnings (P/E) ratio is 49.5.

What does Edwards Lifesciences Corp do?

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.